Galecto Inc (GLTO)

NASDAQ
4.290
-0.070(-1.61%)
Pre Market
4.400
+0.110(+2.56%)
- Real-time Data
  • Volume:
    33,080
  • Bid/Ask:
    4.260/4.530
  • Day's Range:
    4.270 - 4.350

GLTO Overview

Prev. Close
4.29
Day's Range
4.27-4.35
Revenue
-
Open
4.32
52 wk Range
4.03-17.99
EPS
-1.69
Volume
33,080
Market Cap
108.37M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,207,034
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
25,261,832
Next Earnings Date
Sep 01, 2021
What is your sentiment on Galecto Inc?
or
Market is currently closed. Voting is open during market hours.

Galecto Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsSellStrong SellStrong SellStrong SellSell
SummaryStrong SellStrong SellStrong SellStrong SellSell

Galecto Inc Company Profile

Galecto Inc Company Profile

Employees
28

Galecto Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. The Company’s initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (LOXL2). The Company is developing GB0139 for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung. The Company’s product candidate portfolio also includes GB1211, a selective oral galectin-three inhibitor, which is being developed for the treatment of fibrosis related to non-alcoholic steatohepatitis (NASH), and GB2064, a selective oral inhibitor of LOXL2 for the treatment of myelofibrosis, a malignant disease of the bone marrow in which fibrosis reduces the ability to form blood cells.

Read More
  • Back to 5
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.